Tomaxifen 10mg/20mg

About this Medicine

Tomaxifen 10mg and 20mg is a widely recognized medication categorized as a Selective Estrogen Receptor Modulator (SERM). It plays a crucial role in the management and prevention of estrogen receptor-positive (ER+) breast cancer. This condition occurs when cancer cells grow in response to the hormone estrogen. Tomaxifen works by binding to estrogen receptors in breast cells, effectively blocking estrogen from attaching to these receptors. By doing so, it inhibits the growth and proliferation of ER+ breast cancer cells. Primarily prescribed to individuals diagnosed with ER+ breast cancer, Tomaxifen is used both as an adjuvant therapy after surgery, chemotherapy, or radiation, and as a primary treatment in some cases. It is also indicated for reducing the risk of invasive breast cancer in women who have ductal carcinoma in situ (DCIS) and are at high risk, as well as for breast cancer prevention in high-risk women without a diagnosis. Available in two strengths, 10mg and 20mg, Tomaxifen allows healthcare professionals to tailor the dosage to individual patient needs and treatment plans. Understanding the mechanism of Tomaxifen highlights its significance in oncology. As a SERM, its action is selective, meaning it can have both estrogen-like and anti-estrogen-like effects depending on the tissue. In the breast, it acts as an anti-estrogen, which is beneficial for ER+ breast cancer. However, it may have estrogen-like effects in other tissues, such as bone or the uterus, which can influence its overall profile. It is essential for patients to have open discussions with their healthcare provider to fully understand the benefits and potential considerations of Tomaxifen as part of their comprehensive cancer care strategy.